Statement: Only one adverse event is observed in patients from cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 1/25 (4.00%)   Diarrhoea 0/25 (0.00%)   Breast abscess 0/25 (0.00%)   Breast cellulitis 0/25 (0.00%)   Syncope 1/25 (4.00%) Adverse Events 2:   Total: 1/20 (5.00%)   Diarrhoea 1/20 (5.00%)   Breast abscess 1/20 (5.00%)   Breast cellulitis 1/20 (5.00%)   Syncope 0/20 (0.00%)